Nanoparticles Offer Hope for Deadly Brain Cancer Treatment
A South African researcher has received a prestigious research grant to develop nanotechnology aimed at treating one of the most deadly forms of brain cancer.
A New Approach to Glioblastoma
This development reflects growing global interest in creating more precise treatments for brain tumors. Michael Gomez, a doctoral student at the University of the Witwatersrand’s School of Medicine, was awarded the grant by the South African Medical Research Council to support his research into advanced nanomedicine delivery systems for glioblastoma multiforme, a particularly aggressive and fatal cancer.
The Challenges of Glioblastoma
Glioblastoma multiforme is known for its rapid growth and spread, with cells infiltrating surrounding brain tissue. This makes complete surgical removal nearly impossible and often leads to recurrence even after treatment. Currently, even with the best available treatments – surgery, radiation, and chemotherapy – patients typically live for only 12 to 18 months after diagnosis.
Disparities in Access to Care
These challenges are compounded in South Africa and many other African nations due to delayed diagnoses, limited access to specialized neurosurgical services, and the high cost of advanced treatments. This underscores the urgent need for new therapeutic solutions.
Overcoming the Blood-Brain Barrier
Gomez’s research, conducted within the Wits Advanced Drug Delivery Platform, focuses on one of the most significant hurdles in treating brain tumors: the blood-brain barrier. This protective system shields the brain but also prevents many chemotherapy drugs from reaching the tumor in effective concentrations. As Gomez explains, “One of the biggest challenges in treating brain tumors is getting the drug to the right place. The blood-brain barrier prevents many chemotherapy drugs from reaching the tumor at the required dose.”
Comparing Nanoparticle Technologies
The study compares three types of nanoparticle-based drug delivery systems: liposomes (already used in some modern treatments), biodegradable polymer particles (programmable for gradual drug release or response to the tumor environment), and polydopamine nanoparticles – the primary focus of Gomez’s research, which have not been widely explored for brain tumor treatment. Polydopamine is inspired by dopamine, a naturally occurring brain molecule, potentially making it a safer and more effective drug carrier within the nervous system.
Gomez adds, “Because polydopamine is derived from a molecule recognized by the brain, we are investigating whether it can deliver chemotherapy more safely and effectively to patients with brain tumors.”
Leveraging the Glymphatic System
A particularly innovative aspect of the project involves studying the glymphatic system, a recently discovered pathway responsible for distributing cerebrospinal fluid and clearing waste from the brain. Instead of relying on drug passage through the blood and across the blood-brain barrier, the team is exploring the possibility of injecting nanoparticles directly into the cerebrospinal fluid, allowing them to reach the tumor via this natural route. This approach could increase drug concentration within the tumor while reducing toxic effects on the rest of the body.
Frequently Asked Questions
What type of cancer is this research focused on?
The research focuses on glioblastoma multiforme, one of the most aggressive and fatal types of brain cancer.
What is the blood-brain barrier and why is it a challenge?
The blood-brain barrier is a protective system that shields the brain, but it also prevents many chemotherapy drugs from reaching a tumor in effective concentrations.
What is the glymphatic system?
The glymphatic system is a recently discovered pathway responsible for distributing cerebrospinal fluid and clearing waste from the brain.
Could this research lead to more effective treatments for brain cancer in the future?